Market capitalization | $16.96m |
Enterprise Value | $-3.01m |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | 0.06 |
EV/Sales (TTM) EV/Sales | -0.95 |
P/S ratio (TTM) P/S ratio | 5.35 |
P/B ratio (TTM) P/B ratio | 1.06 |
Revenue growth (TTM) Revenue growth | 219.23% |
Revenue (TTM) Revenue | $3.17m |
As a Free StocksGuide user, you can view scores for all 6,914 stocks worldwide.
1 Analyst has issued a forecast Synlogic Inc:
1 Analyst has issued a forecast Synlogic Inc:
Jun '24 |
+/-
%
|
||
Revenue | 3.17 3.17 |
220%
220%
|
|
Gross Profit | -0.68 -0.68 |
85%
85%
|
|
EBITDA | -33 -33 |
46%
46%
|
EBIT (Operating Income) EBIT | -37 -37 |
45%
45%
|
Net Profit | -56 -56 |
14%
14%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Synlogic, Inc. is a clinical-stage biopharmaceutical company. It engages in drug discovery and development of synthetic biotic medicines. The firm focuses on SYNB1020 and SYNB1618, which are orally administered and target hyperammonemia and phenylketonuria. It also works on SYNB1891, an intratumorally administered which treats cancer. The company was founded by Jim Collins and Tim Lu on August 28, 2017, and is headquartered in Cambridge, MA.
Head office | United States |
CEO | Antoine Awad |
Employees | 6 |
Founded | 2017 |
Website | www.synlogictx.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.